|Bid||159.24 x 800|
|Ask||159.84 x 1100|
|Day's Range||158.10 - 159.40|
|52 Week Range||72.67 - 160.03|
|Beta (5Y Monthly)||1.34|
|PE Ratio (TTM)||36.83|
|Earnings Date||Jan 28, 2021 - Feb 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||173.65|
AstraZeneca's (AZN) Enhertu is the first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer.
Zacks.com featured highlights include: Alexion Pharmaceuticals, Adient, Affiliated Managers Group and General Motors
FDA approves Pfizer's (PFE) Xalkori for relapsed or refractory ALK-positive anaplastic large cell lymphoma, a rare form of non-Hodgkin lymphoma (NHL), in pediatric patients and young adults.